Structural biology of the s1p1 receptor

Current Topics in Microbiology and Immunology

Volumn 378, Issue , 2014, Pages 23-53

  Hanson, Michael A ^a   Peach, Robert ^a  

^a Receptos Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; FINGOLIMOD; NIBR 0213; RP 001; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR 1; SPHINGOSINE 1 PHOSPHATE RECEPTOR 1 AGONIST; SPHINGOSINE 1 PHOSPHATE RECEPTOR 1 ANTAGONIST; TASP 0277308; UNCLASSIFIED DRUG; XL 541; DRUG DERIVATIVE; LYSOPHOSPHOLIPID; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; DRUG MECHANISM; EXTRACELLULAR REGION; HUMAN; HYDROGEN BOND; IMMUNOMODULATION; LIGAND BINDING REGION; MOLECULAR BIOLOGY; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN STRUCTURE; RECEPTOR BINDING; RECEPTOR LIGAND INTERACTION; SIGNAL TRANSDUCTION; STRUCTURAL BIOLOGY; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TRANSMEMBRANE REGION; X RAY DIFFRACTION; AMINO ACID SEQUENCE; ANIMAL; BINDING SITE; CHEMISTRY; GENETICS; METABOLISM; MOLECULAR GENETICS; PROTEIN TERTIARY STRUCTURE; REVIEW;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; HUMANS; LYSOPHOSPHOLIPIDS; MOLECULAR SEQUENCE DATA; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE;

EID: 84904270180     PISSN: 0070217X     EISSN: 21969965     Source Type: Book Series    
DOI: 10.1007/978-3-319-05879-5_2     Document Type: Article

References (116)

1. Arnon TI, Xu Y, Lo C et al (2011) GRK2-dependent S1PR1 desensitization is required for lymphocytes to overcome their attraction to blood. Science 333:1898-1903. doi:10.1126/science.1208248
2. Berst F, Grosche P, Janser P, Zecri F (2007) Biaryl sulfonamide derivatives. US Patent Office US 20100029609
3. Brinkmann V (2002) The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277:21453-21457. doi:10.1074/jbc.C200176200
4. Brinkmann V, Pinschewer DD, Feng L, Chen S (2001) FTY720: altered lymphocyte traffic results in allograft protection. Transplantation 72:764-769
5. Caffrey M (2000) A lipid’s eye view of membrane protein crystallization in mesophases. Curr Opin Struct Biol 10:486-497
6. Cahalan SM, Gonzalez-Cabrera PJ, Nguyen N et al (2013) Sphingosine 1-phosphate receptor 1 (S1P1) upregulation and amelioration of experimental autoimmune encephalomyelitis by an S1P1 antagonist. Mol Pharmacol 83:316-321. doi:10.1124/mol.112.082958
7. Cahalan SM, Gonzalez-Cabrera PJ, Sarkisyan G et al (2011) Actions of a picomolar short-acting S1P1 agonist in S1P1-eGFP knock-in mice. Nat Chem Biol 7:254-256. doi:10.1038/nchembio.547
8. Cherezov V (2011) Lipidic cubic phase technologies for membrane protein structural studies. Curr Opin Struct Biol 21:559-566. doi:10.1016/j.sbi.2011.06.007
9. Cherezov V, Rosenbaum DM, Hanson MA et al (2007) High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 318:1258-1265. doi:10.1126/science.1150577
10. Chien EYT, Liu W, Zhao Q et al (2010) Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 330:1091-1095. doi:10.1126/science.1197410
11. Choi JW, Herr DR, Noguchi K et al (2010) LPA receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol 50:157-186. doi:10.1146/annurev.pharmtox.010909.105753
12. Chun J, Goetzl EJ, Hla T et al (2002) International union of pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol Rev 54:265-269
13. Cohen JA, Barkhof F, Comi G et al (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362:402-415. doi:10.1056/NEJMoa0907839
14. Coste O, Brenneis C, Linke B et al (2008) Sphingosine 1-phosphate modulates spinal nociceptive processing. J Biol Chem 283:32442-32451. doi:10.1074/jbc.M806410200
15. Cuvillier O, Pirianov G, Kleuser B et al (1996) Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 381:800-803. doi:10.1038/381800a0
16. Davis MD, Clemens JJ, Macdonald TL, Lynch KR (2005) Sphingosine 1-phosphate analogs as receptor antagonists. J Biol Chem 280:9833-9841. doi:10.1074/jbc.M412356200
17. Deng Q, Clemas JA, Chrebet G et al (2007) Identification of Leu276 of the S1P1 receptor and Phe263 of the S1P3 receptor in interaction with receptor specific agonists by molecular modeling, site-directed mutagenesis, and affinity studies. Mol Pharmacol 71:724-735. doi:10.1124/mol.106.029223
18. Fernandez O, Pozzilli C, Freedman M, et al. (2012) Pharmacodynamic effect, safety and tolerability of ponesimod, a selective sphingosine 1-phosphate receptor-1 modulator, in patients with relapsing-remitting multiple sclerosis. ECTRIMS
19. Filipek S, Stenkamp RE, Teller DC, Palczewski K (2003) G protein-coupled receptor rhodopsin: a prospectus. Annu Rev Physiol 65:851-879. doi:10.1146/annurev.physiol.65.092101.142611
20. Fredriksson R, Lagerström MC, Lundin L-G, Schiöth HB (2003) The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol 63:1256-1272. doi:10.1124/mol.63.6.1256
21. Fujii Y, Hirayama T, Ohtake H et al (2012a) Amelioration of collagen-induced arthritis by a novel S1P1 antagonist with immunomodulatory activities. J Immunol 188:206-215. doi:10.4049/jimmunol.1101537
22. Fujii Y, Ohtake H, Ono N et al (2012b) Lymphopenia induced by a novel selective S1P1 antagonist structurally unrelated to S1P. Biochim Biophys Acta Mol Cell Biol Lipids 1821:600-606. doi:10.1016/j.bbalip.2011.12.006
23. Fujii Y, Ueda Y, Ohtake H et al (2012c) Blocking S1P interaction with S1P1 receptor by a novel competitive S1P1-selective antagonist inhibits angiogenesis. Biochem Biophys Res Commun 419:754-760. doi:10.1016/j.bbrc.2012.02.096
24. Fujita T, Inoue K, Yamamoto S et al (1994) Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. J Antibiot 47:208-215
25. Fyrst H, Saba JD (2010) An update on sphingosine-1-phosphate and other sphingolipid mediators. Nat Chem Biol 6:489-497. doi:10.1038/nchembio.392
26. Gergely P, Wallstrom E, Nuesslein-Hildesheim B, et al. (2009) Phase I study with the selective S1P1/S1P5 receptor modulator BAF312 indicates that S1P1 rather than S1P3 mediates transient heart rate reduction in humans. ECTRIMS
27. Gonzalez-Cabrera PJ, Jo E, Sanna MG et al (2008) Full pharmacological efficacy of a novel S1P1 agonist that does not require S1P-like headgroup interactions. Mol Pharmacol 74:1308-1318. doi:10.1124/mol.108.049783
28. Granier S, Manglik A, Kruse AC et al (2012) Structure of the d-opioid receptor bound to naltrindole. Nature 485:400-404
29. Gräler MH, Goetzl EJ (2004) The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J 18:551-553. doi:10.1096/fj.03-0910fje
30. Haga K, Kruse AC, Asada H et al (2012) Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist. Nature 482:547-551. doi:10.1038/nature10753
31. Hanson MA, Roth CB, Jo E et al (2012) Crystal structure of a lipid G protein-coupled receptor. Science 335:851-855. doi:10.1126/science.1215904
32. Hanson MA, Stevens RC (2009) Discovery of new GPCR biology: one receptor structure at a time. Structure 17:8-14. doi:10.1016/j.str.2008.12.003
33. Hartung J, Olson A, Peach RJ, et al. (2013) Results of a thorough QT/QTc (TQT) study of orally administered RPC1063, a novel, selective S1P1 receptor agonist, in healthy adult volunteers. ECTRIMS
34. Healy LM, Sheridan GK, Pritchard AJ et al (2013) Pathway specific modulation of S1P1 receptor signalling in rat and human astrocytes. Br J Pharmacol 169:1114-1129. doi:10.1111/bph.12207
35. Hla T, Maciag T (1990) An abundant transcript induced in differentiating human endothelial cells encodes a polypeptide with structural similarities to G-protein-coupled receptors. J Biol Chem 265:9308-9313
36. Hobson JP, Rosenfeldt HM, Barak LS et al (2001) Role of the sphingosine-1-phosphate receptor EDG-1 in PDGF-induced cell motility. Science 291:1800-1803. doi:10.1126/science.1057559
37. Holdsworth G, Osborne DA, Pham TT et al (2004) A single amino acid determines preference between phospholipids and reveals length restriction for activation of the S1P4 receptor. BMC Biochem 5:12. doi:10.1186/1471-2091-5-12
38. Hollenstein K, Kean J, Bortolato A et al (2013) Structure of class B GPCR corticotropin-releasing factor receptor 1. Nature 499:438-443. doi:10.1038/nature12357
39. Hurst DP, Grossfield A, Lynch DL et al (2010) A lipid pathway for ligand binding is necessary for a cannabinoid G protein-coupled receptor. J Biol Chem 285:17954-17964. doi:10.1074/jbc.M109.041590
40. Hurst DP, Schmeisser M, Reggio PH (2013) Endogenous lipid activated G protein-coupled receptors: emerging structural features from crystallography and molecular dynamics simulations. Chem Phys Lipids 169:46-56. doi:10.1016/j.chemphyslip.2013.01.009
41. Huwiler A, Kolter T, Pfeilschifter J, Sandhoff K (2000) Physiology and pathophysiology of sphingolipid metabolism and signaling. Biochim Biophys Acta 1485:63-99
42. Huwiler A, Pfeilschifter J (2008) New players on the center stage: sphingosine 1-phosphate and its receptors as drug targets. Biochem Pharmacol 75:1893-1900. doi:10.1016/j.bcp.2007.12.018
43. Ibrahim MA, Johnson HWB, Jeong JW et al (2012) Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists. J Med Chem 55:1368-1381. doi:10.1021/jm201533b
44. Inagaki Y, Pham TT, Fujiwara Y et al (2005) Sphingosine 1-phosphate analogue recognition and selectivity at S1P4 within the endothelial differentiation gene family of receptors. Biochem J 389:187-195. doi:10.1042/BJ20050046
45. Ishii M, Egen JG, Klauschen F et al (2009) Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature 458:524-528. doi:10.1038/nature07713
46. Jaakola V-P, Griffith MT, Hanson MA et al (2008) The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 322:1211-1217. doi:10.1126/science.1164772
47. Jo E, Sanna MG, Gonzalez-Cabrera PJ et al (2005) S1P1-selective in vivo-active agonists from high-throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate. Chem Biol 12:703-715. doi:10.1016/j.chembiol.2005.04.019
48. Kappos L, Radue E-W, O’Connor P et al (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362:387-401. doi:10.1056/NEJMoa0909494
49. Katritch V, Cherezov V, Stevens RC (2012) Diversity and modularity of G protein-coupled receptor structures. Trends Pharmacol Sci 33:17-27. doi:10.1016/j.tips.2011.09.003
50. Kenakin T (2012) The potential for selective pharmacological therapies through biased receptor signaling. BMC Pharmacol Toxicol 13:3. doi:10.1186/2050-6511-13-3
51. Kenakin T, Onaran O (2002) The ligand paradox between affinity and efficacy: can you be there and not make a difference? Trends Pharmacol Sci 23:275-280
52. Kruse AC, Hu J, Pan AC et al (2012) Structure and dynamics of the M3 muscarinic acetylcholine receptor. Nature 482:552-556. doi:10.1038/nature10867
53. Kułakowska A, Zendzian-Piotrowska M, Baranowski M et al (2010) Intrathecal increase of sphingosine 1-phosphate at early stage multiple sclerosis. Neurosci Lett 477:149-152. doi:10.1016/j.neulet.2010.04.052
54. LaMontagne K, Littlewood-Evans A, Schnell C et al (2006) Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res 66:221-231. doi:10.1158/0008-5472.CAN-05-2001
55. Landau EM, Rosenbusch JP (1996) Lipidic cubic phases: a novel concept for the crystallization of membrane proteins. Proc Natl Acad Sci 93:14532-14535
56. Li Z, Chen W, Hale JJ et al (2005) Discovery of potent 3,5-diphenyl-1,2,4-oxadiazole sphingosine-1-phosphate-1 (S1P1) receptor agonists with exceptional selectivity against S1P2 and S1P3. J Med Chem 48:6169-6173. doi:10.1021/jm0503244
57. Lim H-S, Park J-J, Ko K et al (2004) Syntheses of sphingosine-1-phosphate analogues and their interaction with EDG/S1P receptors. Bioorg Med Chem Lett 14:2499-2503. doi:10.1016/j.bmcl.2004.03.001
58. Mandala S, Hajdu R, Bergstrom J et al (2002) Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296:346-349. doi:10.1126/science.1070238
59. Manglik A, Kruse AC, Kobilka TS et al (2012) Crystal structure of the l-opioid receptor bound to a morphinan antagonist. Nature 485:321-326. doi:10.1038/nature10954
60. Napoli KL (2000) The FTY720 story. Ther Drug Monit 22:47-51
61. O’Sullivan C, Dev KK (2013) The structure and function of the S1P1 receptor. Trends Pharmacol Sci 34:401-412. doi:10.1016/j.tips.2013.05.002
62. Ogretmen B, Hannun YA (2004) Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 4:604-616. doi:10.1038/nrc1411
63. Oo ML, Chang S-H, Thangada S et al (2011) Engagement of S1P1-degradative mechanisms leads to vascular leak in mice. J Clin Invest 121:2290-2300. doi:10.1172/JCI45403
64. Oo ML, Thangada S, Wu M-T et al (2007) Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J Biol Chem 282:9082-9089. doi:10.1074/jbc.M610318200
65. Paik JH, Ss Chae, Lee MJ et al (2001) Sphingosine 1-phosphate-induced endothelial cell migration requires the expression of EDG-1 and EDG-3 receptors and Rho-dependent activation of alpha vbeta3- and beta1-containing integrins. J Biol Chem 276:11830-11837. doi:10.1074/jbc.M009422200
66. Palczewski K, Kumasaka T, Hori T et al (2000) Crystal structure of rhodopsin: a G protein- coupled receptor. Science 289:739-745
67. Parrill AL, Baker DL, Wang DA, et al. (2000a) Structural features of EDG1 receptor-ligand complexes revealed by computational modeling and mutagenesis. Ann N Y Acad Sci 905:330-339. doi: 10.1111/j.1749-6632.2000.tb06573.x
68. Parrill AL, Tigyi G (2013) Integrating the puzzle pieces: the current atomistic picture of phospholipid-G protein coupled receptor interactions. Biochim Biophys Acta 1831:2-12. doi:10.1016/j.bbalip.2012.09.002
69. Parrill AL, Wang D, Bautista DL et al (2000b) Identification of Edg1 receptor residues that recognize sphingosine 1-phosphate. J Biol Chem 275:39379-39384. doi:10.1074/jbc.M007680200
70. Pham T-CT, Fells JI, Osborne DA et al (2008a) Molecular recognition in the sphingosine 1-phosphate receptor family. J Mol Graphics Modell 26:1189-1201. doi:10.1016/j.jmgm.2007.11.001
71. Pham THM, Okada T, Matloubian M et al (2008b) S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress. Immunity 28:122-133. doi:10.1016/j.immuni.2007.11.017
72. Pyne NJ, Pyne S (2010) Sphingosine 1-phosphate and cancer. Nat Rev Cancer 10:489-503. doi:10.1038/nrc2875
73. Quancard J, Bollbuck B, Janser P et al (2012) A potent and selective S1P(1) antagonist with efficacy in experimental autoimmune encephalomyelitis. Chem Biol 19:1142-1151. doi:10.1016/j.chembiol.2012.07.016
74. Rasmussen SGF, Choi H-J, Fung JJ et al (2011a) Structure of a nanobody-stabilized active state of the b(2) adrenoceptor. Nature 469:175-180. doi:10.1038/nature09648
75. Rasmussen SGF, DeVree BT, Zou Y et al (2011b) Crystal structure of the b2 adrenergic receptor-Gs protein complex. Nature 477:549-555. doi:10.1038/nature10361
76. Rosen H, Gonzalez-Cabrera PJ, Sanna MG, Brown S (2009) Sphingosine 1-phosphate receptor signaling. Annu Rev Biochem 78:743-768. doi:10.1146/annurev.biochem.78.072407.103733
77. Rosen H, Stevens RC, Hanson M et al (2013) Sphingosine-1-phosphate and its receptors: structure, signaling, and influence. Annu Rev Biochem. doi:10.1146/annurev-biochem-062411-130916
78. Rosenbaum DM, Cherezov V, Hanson MA et al (2007) GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science 318:1266-1273. doi:10.1126/science.1150609
79. Saha AK, Yu X, Lin J et al (2010) Benzofuran derivatives as potent, orally active S1P1 receptor agonists: a preclinical lead molecule for MS. ACS Med Chem Lett 2:97-101. doi:10.1021/ml100227q
80. Sanna MG, Liao J, Jo E et al (2004) Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem 279:13839-13848. doi:10.1074/jbc.M311743200
81. Sanna MG, Wang S-K, Gonzalez-Cabrera PJ et al (2006) Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo. Nat Chem Biol 2:434-441. doi:10.1038/nchembio804
82. Schadel SA, Heck M, Maretzki D et al (2003) Ligand channeling within a G-protein-coupled receptor. The entry and exit of retinals in native opsin. J Biol Chem 278:24896-24903. doi:10.1074/jbc.M302115200
83. Schmouder R, Hariry S, David OJ (2012) Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteers. Eur J Clin Pharmacol 68:355-362. doi:10.1007/s00228-011-1146-9
84. Schürer SC, Brown SJ, Gonzalez-Cabrera PJ et al (2008) Ligand-binding pocket shape differences between sphingosine 1-phosphate (S1P) receptors S1P1 and S1P3 determine efficiency of chemical probe identification by ultrahigh-throughput screening. ACS Chem Biol 3:486-498. doi:10.1021/cb800051m
85. Sherman W, Day T, Jacobson MP et al (2006) Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem 49:534-553. doi:10.1021/jm050540c
86. Shivakumar D, Williams J, Wu Y et al (2010) Prediction of absolute solvation free energies using molecular dynamics free energy perturbation and the OPLS force field. J Chem Theory Comput 6:1509-1519. doi:10.1021/ct900587b
87. Siu FY, He M, de Graaf C et al (2013) Structure of the human glucagon class B G-protein- coupled receptor. Nature 499:444-449. doi:10.1038/nature12393
88. Spiegel S, Milstien S (2003) Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 4:397-407. doi:10.1038/nrm1103
89. Takasugi N, Sasaki T, Suzuki K et al (2011) BACE1 activity is modulated by cell-associated sphingosine-1-phosphate. J Neurosci 31:6850-6857. doi:10.1523/JNEUROSCI.6467-10.2011
90. Tan Q, Zhu Y, Li J et al (2013) Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science 341:1387-1390. doi:10.1126/science.1241475
91. Thompson AA, Liu W, Chun E et al (2012) Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic. Nature 485:395-399. doi:10.1038/nature11085
92. Urbano M, Guerrero M, Rosen H, Roberts E (2013) Modulators of the sphingosine 1-phosphate receptor 1. Bioorg Med Chem Lett. doi:10.1016/j.bmcl.2013.09.058
93. Vachal P, Toth LM, Hale JJ et al (2006) Highly selective and potent agonists of sphingosine-1-phosphate 1 (S1P1) receptor. Bioorg Med Chem Lett 16:3684-3687. doi:10.1016/j.bmcl.2006.04.064
94. Valentine WJ, Kiss GN, Liu J et al (2010) (S)-FTY720-Vinylphosphonate, an analogue of the immunosuppressive agent FTY720, is a pan-antagonist of sphingosine 1-phosphate GPCR signaling and inhibits autotaxin activity. Cell Signal 22:1543-1553. doi:10.1016/j.cellsig.2010.05.023
95. Van Durme J, Horn F, Costagliola S et al (2006) GRIS: glycoprotein-hormone receptor information system. Mol Endocrinol 20:2247-2255. doi:10.1210/me.2006-0020
96. van Loenen PB, van Loenen PB, de Graaf C et al (2011) Agonist-dependent effects of mutations in the sphingosine-1-phosphate type 1 receptor. Eur J Pharmacol 667:105-112. doi:10.1016/j.ejphar.2011.05.071
97. Venkatakrishnan AJ, Deupi X, Lebon G et al (2013) Molecular signatures of G-protein-coupled receptors. Nature 494:185-194. doi:10.1038/nature11896
98. Visentin B, Vekich JA, Sibbald BJ et al (2006) Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 9:225-238. doi:10.1016/j.ccr.2006.02.023
99. Vroling B, Sanders M, Baakman C et al (2011) GPCRDB: information system for G protein- coupled receptors. Nucleic Acids Res 39:D309-D319. doi:10.1093/nar/gkq1009
100. Wacker D, Wang C, Katritch V et al (2013) Structural features for functional selectivity at serotonin receptors. Science 340:615-619. doi:10.1126/science.1232808
101. Wang C, Jiang Y, Ma J et al (2013a) Structural basis for molecular recognition at serotonin receptors. Science 340:610-614. doi:10.1126/science.1232807
102. Wang C, Wu H, Katritch V et al (2013b) Structure of the human smoothened receptor bound to an antitumour agent. Nature 497:338-343. doi:10.1038/nature12167
103. Wang DA, Lorincz Z, Bautista DL et al (2001) A single amino acid determines lysophospholipid specificity of the S1P1 (EDG1) and LPA1 (EDG2) phospholipid growth factor receptors. J Biol Chem 276:49213-49220. doi:10.1074/jbc.M107301200
104. Warne T, Serrano-Vega MJ, Baker JG et al (2008) Structure of a beta1-adrenergic G-protein-coupled receptor. Nature 454:486-491. doi:10.1038/nature07101
105. Welch SP, Sim-Selley LJ, Selley DE (2012) Sphingosine-1-phosphate receptors as emerging targets for treatment of pain. Biochem Pharmacol 84:1551-1562. doi:10.1016/j.bcp.2012.08.010
106. Whetzel AM, Bolick DT, Srinivasan S et al (2006) Sphingosine-1 phosphate prevents monocyte/ endothelial interactions in type 1 diabetic NOD mice through activation of the S1P1 receptor. Circ Res 99:731-739. doi:10.1161/01.RES.0000244088.33375.52
107. White JF, Noinaj N, Shibata Y et al (2012) Structure of the agonist-bound neurotensin receptor. Nature 490:508-513. doi:10.1038/nature11558
108. Wu B, Chien EYT, Mol CD et al (2010) Structures of the CXCR4 chemokine GPCR with small- molecule and cyclic peptide antagonists. Science 330:1066-1071. doi:10.1126/science.1194396
109. Wu H, Wacker D, Mileni M et al (2012) Structure of the human j-opioid receptor in complex with JDTic. Nature 485:327-332. doi:10.1038/nature10939
110. Xia P, Gamble JR, Wang L et al (2000) An oncogenic role of sphingosine kinase. Curr Biol 10:1527-1530. doi:10.1016/S0960-9822(00)00834-4
111. Xu H, McElvain M, Fiorino M et al (2013) Predictability of peripheral lymphocyte reduction of novel S1P1 agonists by in vitro GPCR signaling profile. J Biomol Screen. doi:10.1177/1087057113488629
112. Yan L, Huo P, Doherty G et al (2006) Discovery of 3-arylpropionic acids as potent agonists of sphingosine-1-phosphate receptor-1 (S1P1) with high selectivity against all other known S1P receptor subtypes. Bioorg Med Chem Lett 16:3679-3683. doi:10.1016/j.bmcl.2006.04.084
113. Yan L, Huo P, Hale JJ et al (2007) SAR studies of 3-arylpropionic acids as potent and selective agonists of sphingosine-1-phosphate receptor-1 (S1P1) with enhanced pharmacokinetic properties. Bioorg Med Chem Lett 17:828-831. doi:10.1016/j.bmcl.2006.10.057
114. Zhang C, Srinivasan Y, Arlow DH et al (2012) High-resolution crystal structure of human protease-activated receptor 1. Nature 492:387-392. doi:10.1038/nature11701
115. Zhang H, Desai NN, Olivera A et al (1991) Sphingosine-1-phosphate, a novel lipid, involved in cellular proliferation. J Cell Biol 114:155-167
116. Zipp F, Vollmer TL, Selmaj K, Bar-Or A (2012) Efficacy and safety of the S1P receptor agonist ONO-4641 in patients with relapsing-remitting multiple sclerosis: results of a 26-week, double-blind, placebo-controlled, Phase II trial (DreaMS). ECTRIMS